Bleeding Risk in Patients with Peripheral Arterial Disease
Open Access
Abstract
Patients with peripheral arterial disease (PAD) are at high risk of major adverse cardiac events (MACE) and major adverse limb events (MALE). Recently, antithrombotic therapies employing antiplatelet and anticoagulant drugs have proven to be valid in reducing MACE in patients with PAD and polyvascular disease and MALE, particularly in patients who have already been revascularized and remain at increased risk of MALE. However, more aggressive antithrombotic therapies lead to an increased risk of bleeding. Antithrombotic therapy and revascularization procedures entail an increased hemorrhagic risk that is also linked to having received more vigorous antithrombotic therapies. Therefore, it appears crucial to have specifically targeted scores for a PAD patient to assess bleeding and thrombotic risks. The correct utilization of a risk score will determine the variable risk factors for bleeding that can be corrected or modified, as well as identify patients at high risk that require regular reexamination and follow-up. Clinical risk scores do not represent the absolute reality, and inter-score variability must be taken into account. Moreover, several risk scores have been created to be basic and to facilitate and improve clinical decisions in daily practice. Many risk scores based on points vary according to the configuration of the studies, population type, and ethnic group, and many of the risk factor elements in a specific score are unlikely to sustain same weight for that risk. The best approach continues to be devising an uncomplicated, functional, validated, and precise score that can be adjusted to different clinical contexts and populations, while considering the mutable composition of clinical risk.Keywords
This publication has 24 references indexed in Scilit:
- Predictors of Bleeding in Patients with Symptomatic Peripheral Artery Disease: A Cohort Study Using The Health Improvement Network in the United KingdomThrombosis and Haemostasis, 2018
- Rivaroxaban with or without Aspirin in Stable Cardiovascular DiseaseNew England Journal of Medicine, 2017
- Bleeding Risk Profile in Patients With Symptomatic Peripheral Artery DiseaseJournal of Endovascular Therapy, 2016
- Comparison of global estimates of prevalence and risk factors for peripheral artery disease in 2000 and 2010: a systematic review and analysisThe Lancet, 2013
- A Novel User-Friendly Score (HAS-BLED) To Assess 1-Year Risk of Major Bleeding in Patients With Atrial FibrillationChest, 2010
- Risk score to predict serious bleeding in stable outpatients with or at risk of atherothrombosisEuropean Heart Journal, 2010
- Bleeding Increases the Risk of Ischemic Events in Patients With Peripheral Arterial DiseaseCirculation, 2009
- Dual Antithrombotic Therapy Increases Severe Bleeding Events in Patients With Stroke and Cardiovascular DiseaseStroke, 2008
- Adverse Impact of Bleeding on Prognosis in Patients With Acute Coronary SyndromesCirculation, 2006
- Clinical classification schemes for predicting hemorrhage: Results from the National Registry of Atrial Fibrillation (NRAF)American Heart Journal, 2006